Special Combination of OBP-301 and Pembrolizumab
This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.
Advanced Solid Tumor
BIOLOGICAL: OBP-301|DRUG: Pembrolizumab
Dose limiting toxicity (DLT), Dose limiting toxicity, 4weeks
Response rate (RR), Response rate by RECIST ver. 1.1, 3 years|Progression free survival (PFS), Progression free survival, 3 years|Rate of adverse event, Rate of adverse event, 3 years
Biomarkers:Efficacy evaluations according to immune status, Immune status will be analyzed using biopsy and blood samples by flow cytometry, RNA seq, whole exome sequencing, and immunohistochemistry, etc., 3 years
Phase 1a part:

To evaluate safety and tolerability in combination of OBP-301 and Pembrolizumab in patient with advanced or metastatic solid tumor and to determine recommended dose in phase 1b part.

Phase 1b part:

To evaluate safety and potential efficacy in combination of OBP-301 and Pembrolizumab in patients in expanded arm.